Citation Impact
Citing Papers
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
2008
ESUR prostate MR guidelines 2012
2012 Standout
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement
2015 Standout
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
2016
Reporting methods in studies developing prognostic models in cancer: a review
2010
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate
2011
RNAscope
2011 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
2015 Standout
Do Prognostic Parameters of Remission versus Relapse after Bacillus Calmette–Guérin (BCG) Immunotherapy Exist? Analysis of a Quarter Century of Literature
2003
Mechanisms of Thrombus Formation
2008 Standout
Optimal Management of the T1G3 Bladder Cancer
2005
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
2015 Standout
Towards better clinical prediction models: seven steps for development and an ABCD for validation
2014 Standout
REVIEW: Plasminogen Activator Inhibitor‐1 (PAI‐1): A Key Factor Linking Fibrinolysis and Age‐Related Subclinical and Clinical Conditions
2010
T1G3 Bladder Tumours: The Case for Radical Cystectomy
2003
Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors
2009
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review
2011
Guidelines on Bladder Cancer
2002
Prognostic significance of autoimmunity during treatment of melanoma with interferon
2011
Epidemiology of Prostate Cancer
2019 Standout
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
2013 Standout
uPA AND PAI-1 In Breast Cancer: Review Of Their Clinical Utility And Current Validation In The ProspectivE NNBC-3 TRIAL
2008
Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects
2009 Standout
Merkel cell carcinoma
2017
Regulation of glutathione synthesis
2008 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance
2006
Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
2007
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Urothelial Carcinoma of the Prostate
2007
N-acetylcysteine attenuates TNF-α induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes
2006
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
2016 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Bladder cancer
2016 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guérin
2011
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
Bacillus Calmette‐Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression
2004
Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock
2004
Cancer immunotherapy comes of age
2011 StandoutNature
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
2013 Standout
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Reactive oxygen species have a causal role in multiple forms of insulin resistance
2006 StandoutNature
Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder
2005
IgG4-related disease
2014 Standout
Epidemiology and Risk Factors of Urothelial Bladder Cancer
2012 Standout
Reporting performance of prognostic models in cancer: a review
2010
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement
2015 Standout
Bladder cancer: Epidemiology, staging and grading, and diagnosis
2005 Standout
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
2005
Mitochondria and cancer
2012 Standout
Cystectomy in Patients with High Risk Superficial Bladder Tumors Who Fail Intravesical BCG Therapy:
2005
Treatment Options Available for Bacillus Calmette-Guérin Failure in Non–muscle-invasive Bladder Cancer
2012
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
Invasive T1 bladder cancer: indications and rationale for radical cystectomy
2008
EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
2011
Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature
2012
Revisiting the biological roles of PAI2 (SERPINB2) in cancer
2008
Natural History, Recurrence, and Progression in Superficial Bladder Cancer
2006
DNA methylation GrimAge strongly predicts lifespan and healthspan
2019 Standout
A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study
2007
RESTAGING TRANSURETHRAL RESECTION OF HIGH RISK SUPERFICIAL BLADDER CANCER IMPROVES THE INITIAL RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY
2005
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Matrix remodeling stimulates stromal autophagy, “fueling” cancer cell mitochondrial metabolism and metastasis
2011
Bladder Cancer
2020 Standout
Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update
2007
Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus
2019 StandoutNobel
Sympathetic Innervation Regulates Basement Membrane Thickening and Pericyte Number in Rat Retina
2005
Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway.
2016
Fibrohistiocytic Tumors and Related Neoplasms in Children and Adolescents
2012
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update
2012
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics
2017 StandoutNobel
Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles
2009
Human platelets synthesize and express functional tissue factor
2007
Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence Cystoscopy
2004
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
2015 Standout
Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma
2003
Glutathione depletion up‐regulates Bcl‐2 in BSO‐resistant cells
2004
Works of Sergio Almenar being referenced
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer
2007
Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1‐PDGFB ) study with therapeutic implications
2009
Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity
2005
Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers
2005
Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Specimens
2005
THE 3-MONTH CLINICAL RESPONSE TO INTRAVESICAL THERAPY AS A PREDICTIVE FACTOR FOR PROGRESSION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER CANCER
2000
The optimum timing of radical cystectomy for patients with recurrent high‐risk superficial bladder tumour
2004
Quantitative Real-Time Reverse Transcription-PCR Assay for Urokinase Plasminogen Activator, Plasminogen Activator Inhibitor Type 1, and Tissue Metalloproteinase Inhibitor Type 1 Gene Expressions in Primary Breast Cancer
2002
RISK GROUPS IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: STATISTICAL AND CLINICAL MODEL IMPROVING HOMOGENEITY
2005
Problems in Defining Melanoma Regression and Prognostic Implication
2009
Clinical Panurothelial Disease in Patients with Superficial Bladder Tumors: Therapeutic Implications
2002
The Prostate Involvement As Prognostic Factor in Patients with Superficial Bladder Tumors
1995
Regresión en el melanoma: problemas en su definición e implicación pronóstica
2009
THE 3-MONTH CLINICAL RESPONSE TO INTRAVESICAL THERAPY AS A PREDICTIVE FACTOR FOR PROGRESSION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER CANCER
2000
Extravesical Involvement in Patients with Bladder Carcinoma In Situ: Biological and Therapy Implications
1996